Suzhou Zion Pharma Technology Co. Ltd. has described transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) and/or probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors reported to be useful for the treatment of cancer and viral infections.